Advertisement

Topics

Latest "Addiction Treatment Advocacy Coalition" News Stories

09:01 EST 18th February 2019 | BioPortfolio

Here are the most relevant search results for "Addiction Treatment Advocacy Coalition" found in our extensive news archives from over 250 global news sources.

More Information about Addiction Treatment Advocacy Coalition on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Addiction Treatment Advocacy Coalition for you to read. Along with our medical data and news we also list Addiction Treatment Advocacy Coalition Clinical Trials, which are updated daily. BioPortfolio also has a large database of Addiction Treatment Advocacy Coalition Companies for you to search.

Showing "Addiction Treatment Advocacy Coalition" News Articles 1–25 of 16,000+

Monday 18th February 2019

Asana BioSciences to Present Correlation Between Microbiome Changes and Clinical Efficacy With JAK/SYK Inhibitor ASN002 in the Late-Breaking News Session at the American Academy of Dermatology (AAD) Annual Congress

First demonstration of changes in Staphylococcus aureus in lesional skin, correlating with clinical efficacy Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN002 data demonstrating changes in skin microbiome and correlation with clinical efficacy in patients with moderate-to-severe atopic dermat...


Innovate UK awards AKLRD £675,000 for osteoarthritis drug

AKL Research and Development’s early-stage osteoarthritis drug has won a prestigious award from Innovate UK, as a potential “game-changing” treatment.

Darolutamide shows promise for treatment of prostate cancer

Orion's and Bayer's darolutamide has shown substantial efficacy in the treatment of prostate cancer.


United States Neurovascular Embolization Procedures Outlook to 2025 [Report Updated: 15112018] Prices from USD $2995

United States Neurovascular Embolization Procedures Outlook to 2025SummaryGlobalData's new report, United States Neurovascular Embolization Procedures Outlook to 2025, provides key procedures data on the United States Neurovascular Embolization Procedures. The report provides procedure volumes within market segments Aneurysm Clipping Procedures, Embolization Coiling Procedures, Flow Diversion Ste...

Cannabidiol Use in Refractory Epilepsy

The recent FDA approval of cannabidiol provides another treatment option for refractory epilepsy. Find out what there is to know. Pediatric Pharmacotherapy

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that the pair “significantly extended” median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC). Specifically, when used as a first-line treatment, the combo therapy improved median PFS by five months compared to Pfizer’s S...

New Allergy Treatment Program Aims to Improve Patient Care and Reduce Healthcare Costs

Through an investment in Xtract Solutions, a software provider for hospitals and allergy clinics, Edge Pharmacy Services creates the first complete solution to provide compliant immunotherapy. The program includes tracking for diagnostics and injections, USP 797 compliance, compounding assistance, and easy outsourcing for facilities unable to mix treatment serums in-house. COLCHESTER, Vt. (PRWEB) ...

Texas Recovery Center in Austin New Hope Ranch Launches New Website

New Hope Ranch is happy to announce the launch of its new website AUSTIN, Texas (PRWEB) February 18, 2019 New Hope Ranch is happy to announce the launch of its new website at https://www.newhoperanch.com/. The new website is responsive, making it easy to access from smartphones and tablets in addition to laptops and desktops. Since many website visitors surf the internet using mobile devices, de...

MSD's Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal cell carcinoma (RCC) and delayed disease progression and death according to the results of a Phase 3 clinical trial. The combo outperformed Pfizer’s Sutent – the current standard of care first line treatment for advanced RCC patients. read m...

Hypofractionated radiotherapy should be considered new practice standard for men with low-risk prostate cancer

Results from a clinical study (NRG-RTOG 0415) determined that a hypofractionated radiotherapy schedule (H-RT), a treatment schedule that delivers a total dose of radiotherapy over a shorter period of time, is not worse than the conventional radiotherapy...

Why some brain tumours respond to immunotherapy

Researchers have learned why some glioblastomas, which are the most common type of brain cancer respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the...

Bavencio plus Inlyta improves median PFS in renal carcinoma study

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced The post Bavencio plus Inlyta improves median PFS in renal carcinoma study appeared first on Pharmaceutical Business review.

New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program

- Specialised Therapeutics Asia to make NERLYNX® (neratinib) available to women in Singapore - Five-year follow up data shows NERLYNX reduces risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer[1] - Subsidised Singapore Special Access Program open today to patients with HER2-overexpressing cancers ...

Saniona AB: Saniona's SAN711 selected for clinical studies in itching and pain

PRESS RELEASE February 18, 2019 SAN711 has achieved preclinical validation and met other requirements for clinical studyFirst in class compound offers a new treatment paradigm for itching and neuro...

Sunday 17th February 2019

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

Precision radiotherapy effective in inoperable lung cancer

A newly developed and highly precise radiotherapy technique has been shown to produce greater survival rates in patients with inoperable non-small cell lung cancer (NSCLC) compared to conventional radiotherapy. Stereotactic ablative body radiotherapy (SABR) is a highly targeted technique for delivering very high radiotherapy doses targeted at a patient’s tumour. Unlike conventional radiotherapy...

'Cellular barcoding' pinpoints cells responsible for spread of cancer

Researchers have used a technique called cellular barcoding to tag, track and pinpoint cells responsible for the spread of breast cancer from the main tumour into the blood and other organs. Dr Delphine Merino, Dr Tom Weber, Professor Jane Visvader, Professor Geoffrey Lindeman and Dr Shalin Naik led the research that involved breast cancer biologists, clinician scientists, biotechnologists and co...

sorbion GmbH Co KG Medical Equipment Deals and Alliances Profile [Report Updated: 11122018] Prices from USD $250

Summarysorbion GmbH Co KG sorbion, a subsidiary of BSN medical GmbH is a health care provider that produces and sells medical products for wound treatment. The company offers products such as sorbion sachet EXTRA, sorbion sachet multi star, sorbion sachet S, sorbion sachet S drainage, sorbion sana XL, sorbion silver flex, sorbion sachet XL, and others. It provides innovative dressings for the tre...

Vincenzo Palermo @vincepalermo

RT @semodough: $INCY FDA granted Breakthrough Therapy designation for pemigatinib in treatment of FGFR2 translocated cholangiocarcinoma. ex…

An investment fund that has financed the building of Britain’s first proton beam therapy centres for cancer treatment is gearing up for a £320m float https://www.thetimes.co.uk/edition/business/neil-woodford-eyes-320m-float-of-proton-beam-clinics-8cqvw

An investment fund that has financed the building of Britain’s first proton beam therapy centres for cancer treatment is gearing up for a £320m float https://www.thetimes.co.uk/edition/business/neil-woodford-eyes-320m-float-of-proton-beam-clinics-8cqvw8g8w?utm_medium=Social&utm_source=Twitter#Echobox=1550346247 …

Saturday 16th February 2019

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent Data Consistent Across all IMDC Risk Groups and Regardless of PD-L1 Expression Merck (NYSE: MRK), known as MSD ou...

Bladder Ca Treatment Enters 'Post-Checkpoint' Era

(MedPage Today) -- Early trials show responses with monoclonal antibody-drug conjugates

Heightened #Cocaine Addiction and Motivation in Women Linked to Hormones (with video): http://ow.ly/oSDu30nESHU pic.twitter.com/aIs2IXnFwB

Heightened #Cocaine Addiction and Motivation in Women Linked to Hormones (with video): http://ow.ly/oSDu30nESHU  pic.twitter.com/aIs2IXnFwB

$AMGN Granted FDA ODD for the treatment of Acute Myeloid Leukemia https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=675018 …

$AMGN Granted FDA ODD for the treatment of Acute Myeloid Leukemia https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=675018 …

$BHVN verdiperstat granted FDA ODD for the Treatment of multiple system atrophy (MSA) https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=671418 …

$BHVN verdiperstat granted FDA ODD for the Treatment of multiple system atrophy (MSA) https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=671418 …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks